C12N 2710/10333
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/10333 (Use of viral protein as therapeutic agent other than vaccine) appears on 30 US grants and 46 published applications in this corpus.
Search patents in C12N- Granted patents
- 30
- Published applications
- 46
- Assignees
- 31
- Inventors
- 55
- Latest grant
- 11 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 4 |
| 2015 | 1 | 2 |
| 2016 | 2 | 3 |
| 2017 | 5 | 6 |
| 2018 | 2 | 5 |
| 2019 | 4 | 7 |
| 2020 | 3 | 3 |
| 2021 | 3 | 2 |
| 2022 | 5 | 1 |
| 2023 | 2 | 2 |
| 2024 | 1 | 5 |
| 2025 | 2 | 2 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Desmoglein 2 (DSG2) binding proteins and uses therefor11 Nov 2025US 12,466,859 B2University of Washington through its Center for Commercialization
- Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity25 Feb 2025US 12,233,130 B2Defence Therapeutics Inc.
- Immunomodulatory fusion proteins6 Aug 2024US 12,054,530 B2EpicentRx, Inc.
- Desmoglein 2 (DSG2) binding proteins and uses therefor21 Nov 2023US 11,820,795 B2University of Washington
- Synthetic adenoviruses with tropism to damaged tissue for use in promoting wound repair and tissue regeneration22 Aug 2023US 11,730,781 B2The Salk Institute for Biological Studies
- Recombinant oncolytic adenovirus for cancer therapy20 Aug 2026US 2026/0240928 A1The Johns Hopkins University
- Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity23 Jul 2026US 2026/0207765 A1Defence Therapeutics Inc.
- Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof6 Mar 2025US 2025/0074950 A1Board of Regents, The University of Texas System
- Immunomodulatory fusion proteins6 Mar 2025US 2025/0074967 A1EpicentRx, Inc.
- Universal t cell and appication thereof10 Oct 2024US 2024/0335535 A1St Phi Therapeutics Co., Ltd.
Most cited
By later US patents
- Desmoglein 2 (DSG2) binding proteins and uses therefor8US 10,150,798 B2University of Washington through its Center for Commercialization · 2018
- Affenadenovirus (gorilla) or adenoviral vectors and methods of use8US 10,272,162 B2GenVec, Inc. · 2019
- Detargeted adenovirus variants and related methods8US 10,376,549 B2Adcure Biotechnologies, LLC. · 2019
- Desmoglein 2 (DSG2) binding proteins and uses therefor8US 10,611,803 B2University of Washington through its Center for Commercialization · 2020
- Desmoglein 2 (DSG2) binding proteins and uses therefor8US 9,688,727 B2University of Washington · 2017